![]() One person died, and another patient is in critical condition. The clots occurred in veins that drain blood from the brain and occurred together with low platelets. In the U.S., the only country using the vaccine, all six cases were among women between the ages of 18 and 48, and symptoms occurred six to 13 days after vaccination. to make this decision, and what it could mean for Canada. Here's what we know about what led the U.S. Centers for Disease Control and Prevention and the Food and Drug Administration (FDA) said in a joint statement they are investigating blood clots in six women in the days after vaccination, in combination with reduced platelet counts.Ĭanada has approved the vaccine but hasn't yet received any doses. recommended putting on hold the use of the single-dose Johnson & Johnson COVID-19 vaccine. The company said last summer it planned to deliver 1 billion doses of the one-shot treatment in 2021, but fell far short with roughly 400 million doses, one source close to the matter told the Times.On Tuesday, the U.S. REUTERS/ Sumaya Hisham/File Photoīut plans are underway for J&J to start production of its vaccine at two other facilities in late spring, including one in India and another in North Carolina.Ī J&J spokesman told the Times the company was “working day and night” to fight the COVID-19 pandemic - with millions of doses stockpiled away in inventory. Johnson & Johnson’s COVID-19 vaccine has been linked to a rare but dangerous blood-clot disorder. The Food and Drug Administration is insisting on reviewing individual batches of the vaccine before shipment and regulators haven’t approved any made since the factory reopened, a spokesman for the contractor said. It then restarted in August, but regulators haven’t yet found it can operate in compliance with manufacturing standards, officials told the Times. Johnson & Johnson hired a contractor to start producing its vaccine at a Baltimore plant capable of producing a billion doses per year, but regulators shut it down last April. Other facilities have been tasked to produce the Johnson & Johnson vaccine. Once restarted, doses made at the plant won’t be shipped until May or June, according to the report. The Leiden plant had the capacity to produce more than 50 million doses per month, the Times reported. Still, poorer countries rely on Johnson & Johnson’s version since it doesn’t require ultra-cold storage. Johnson & Johnson’s COVID-19 vaccine has been linked to a rare but dangerous blood-clot disorder and some studies found it performs worse than its Pfizer and Moderna counterparts. Johnson & Johnson has temporarily suspended production at a key plant manufacturing the COVID-19 vaccine. Johnson & Johnson is one of several companies trying to develop the first vaccine against it. RSV, which causes mild, cold-like symptoms, kills an estimated 14,000 older Americans each year. The vaccine is not expected to be available for several years even if it’s proven effective. The plant has since been manufacturing a vaccine against respiratory syncytial virus (RSV) to be used in a clinical trial in older adults in wealthy countries, a source close to the matter told the Times. The facility in the Dutch city of Leiden has instead shifted its efforts to produce an experimental vaccine to treat an unrelated virus, according to the report. Johnson & Johnson had already fallen behind on deliveries of its one-shot COVID-19 vaccine to poorer countries. Other facilities have been tasked to produce the J&J vaccine, but they either still await regulatory approval or weren’t yet manufacturing it, the Times reported. ![]() While it’s unclear if the shutdown that began late last year has had an impact on vaccine availability, it could slash Johnson & Johnson’s supply by a few hundred million doses, one source told the newspaper. The stoppage at the plant in the Netherlands is temporary - with production of the vaccine expected to resume sometime in March, the New York Times reported, citing sources close to the matter. Johnson & Johnson stopped production of its single-shot COVID-19 vaccine at the only plant making usable doses late last year, according to a report Tuesday. NY’s Hochul quietly scraps $64M Excelsior COVID vax app due to $200K monthly costs and fact no one uses it anymore ![]() Biden admin thinks it has divine right to nix conservatives’ free speech rightsĬDC boss’ utterly laughable exit warning on politicized ‘science’Īgeism in NYC is a serious issue with 29% of NYers believing seniors shouldn’t work: poll ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |